Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Basics

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 05, 2020 3:31pm

113 Views

Post# 31668185

RE:RE:RE:RE:RE:RE:RE:Basics

The actually do own all the rights to Egrifta, which is the drug they are testing in NASH. If you are convinced that the NASH phase III happens, then you should be a happy investor.

Dcutter101 wrote: I definitely think phase 3 happens, but they could be second or third drug approved by then, and if they don't own all the rights, then the payoff is muted? If I understand the rights part.... I did buy some lotto tickets - so I hope the cancer news is more promising then I understand it

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features